Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment o...

Full description

Bibliographic Details
Main Authors: Young-Suk Lim, W. Ray Kim, Douglas Dieterich, Jia-Horng Kao, John F. Flaherty, Leland J. Yee, Lewis R. Roberts, Homie Razavi, Patrick T. F. Kennedy
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Viruses
Subjects:
hepatitis B
cirrhosis
hepatocellular carcinoma
liver fibrosis
viral hepatitis
Online Access:https://www.mdpi.com/1999-4915/15/4/997

Internet

https://www.mdpi.com/1999-4915/15/4/997

Similar Items